- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
F.T.C. Clears Express Scripts-Medco Deal
Express Scripts
Medco Health Solutions
Regulators have given their blessing for to buy , the final hurdle in a $29 billion deal creating the nation’s largest pharmacy benefits provider.
The Federal Trade Commission voted 3 to 1 to approve the acquisition on Monday, ending an eight-month inquiry into whether the deal would stifle competition in the pharmacy benefits industry. The agency’s approval is the closing of one of the largest deals of 2011, and one that was the subject of a lot of antitrust concerns.
Read the full story: http://hcp.lv/HaFrKZ
Source: The New York Times
Streamlining "Brain-to-Vein" Time, Patient Selection, Imperative for Implementing CAR T for MM
March 21st 2025Ajai Chari, MD, University of California San Francisco, explores the challenges that accompany integrating chimeric antigen receptor (CAR) T-cell therapies into multiple myeloma treatment.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Overcoming CAR T Manufacturing Failure in LBCL
March 21st 2025Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen receptor (CAR) T-cell administration in patients with relapsed/refractory large B-cell lymphoma (LBCL).
Read More
